# Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

> **NCT00003144** · PHASE1 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 44 (estimated)

## Conditions studied

- Drug/Agent Toxicity by Tissue/Organ
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** amifostine trihydrate
- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00003144
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-08
- **Primary completion:** 2001-04
- **Final completion:** —
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2011-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003144, "Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00003144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*